Loading the catalog…
Loading the catalog…
海思科自主研发的创新药 HSK42360-Na 片正式被国家药监局药品审评中心纳入《突破性治疗品种名单》,用于治疗 BRAFV600 突变的复发或进展性高级别脑胶质瘤。该药为 BRAF 悖论破坏剂抑制剂,中枢神经系统渗透性优异,已开展的临床试验显示疗效突出且安全性可控,纳入突破性治疗后有望在上市申报阶段获得优先审评资格,加速上市进程。
What RADAR observed and classified to build this opportunity. It is what the source published, not a verification that the offer is still active.
海思科:创新药 HSK42360-Na 片纳入突破性治疗药物程序. 海思科自主研发的创新药 HSK42360-Na 片正式被国家药监局药品审评中心纳入《突破性治疗品种名单》,用于治疗 BRAFV600 突变的复发或进展性高级别脑胶质瘤。该药为 BRAF 悖论破坏剂抑制剂,中枢神经系统渗透性优异,已开展的临床试验显示疗效突出且安全性可控,纳入突破性治疗后有望在上市申报阶段获得优先审评资格,加速上市进程。
Open sourceThe catalog shows persisted RADAR opportunities. Storage availability does not mean sources are verified or offers are active.